SCHEMBL17049219

SCHEMBL17049219

C=CC[C@H](C)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL57503 1.00
SCHEMBL25983900 0.87 TSHR (0.39)
SCHEMBL11115038 0.85 TSHR (0.37)
SCHEMBL87843 0.84
Ethylene SCHEMBL21634076 0.82 TSHR (0.40)
SCHEMBL564664 0.82 TSHR (0.42)
SCHEMBL28096163 0.82 TSHR (0.35)
SCHEMBL25172364 0.80 TSHR (0.46)
SCHEMBL632478 0.80 TSHR (0.46)
SCHEMBL9773418 0.80 TSHR (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3133747-A1 METHOD AND APPARATUS FOR TRANSMITTING AND FEEDING BACK SIGNAL Huawei Technologies Co., Ltd. (CN) 2017-02-22 EP disclosed
EP-3110429-A1 ADOPTIVE CELLULAR THERAPY USING AN AGONIST OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA &amp; RELATED THERAPEUTIC METHODS Lycera Corporation (US) 2017-01-04 EP disclosed
WO-2015131035-A1 ADOPTIVE CELLULAR THERAPY USING AN AGONIST OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA &amp; RELATED THERAPEUTIC METHODS LYCERA CORPORATION (US) 2015-09-03 WO disclosed